The absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan was investigated in healthy male subjects by administration of 14C-labeled compound.
Weber, Cornelia +2 more
core
Activin A-Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH. [PDF]
Faizah NN +6 more
europepmc +1 more source
Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping and dynamic trajectories. [PDF]
Yu X +10 more
europepmc +1 more source
Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS). [PDF]
Han L +7 more
europepmc +1 more source
Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. [PDF]
Habib NG +4 more
europepmc +1 more source
Successful treatment of refractory chilblain lupus erythematosus with bosentan. [PDF]
Gunawardana S +3 more
europepmc +1 more source
A K<sub>Ca</sub> 2.2/2.3 Opener Reverses ET-1-Induced NLRP3 Activation in Hypertensive Mice Corpora Cavernosa. [PDF]
Sobrano Fais R +6 more
europepmc +1 more source
Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes
Experimental evidence suggests that endothelin 1 (ET-1) is involved in the development of retinal microvascular abnormalities induced by diabetes. The effects of ET-1 are mediated by endothelin A- and B-receptors (ETA and ETB).
Hernández Pascual, Cristina +13 more
core
Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries. [PDF]
Hirono K +17 more
europepmc +1 more source
Silver nanoparticles-based green fluorescent probe for determination of Bosentan in pharmaceutical formulation and spiked plasma samples. [PDF]
Trabik YA +3 more
europepmc +1 more source

